$249.04 2.62 (1.04%)
19:23 EDT AMGN Stock Quote Delayed 30 Minutes
Previous Close $249.04
Market Cap 164.79B
PE Ratio 79.06
Volume (Avg. Vol.) 1.33M
Day's Range 247.07 - 251.57
52-Week Range 173.12 - 264.97
Dividend & Yield 5.28 (2.12%)
AMGN Stock Predictions, Articles, and Amgen News
- From InvestorPlace
- From the Web
These big-name stocks are showing new signs of life, making each an ideal company for your list of stocks to buy.
AMGN stock has seen a steady incline since May and one that has good odds of continuing. This is sponsored by a general bid in the healthcare and biotechnology sectors.
Drug stocks have been beaten up ever since the 2015 collapse of Valeant, but many of them are now too cheap to ignore.
There’s a lot uncertainty in today’s market, but one thing is guaranteed ... The new tax reform law is about to cause an avalanche of money to rush into dividend stocks in the weeks and months ahead.
Healthcare stocks are now a leading sector. Here are three components worth having on your radar this week for bullish trades.
Large-cap biotech stocks as a group rallied along with the broader stock market on Wednesday. While so doing, some big names like AMGN stock broke past key near-term technical resistance.
The biotech sector peaked in 2015. While it bounced back from lows, biotech ETFs give investors exposure to the sector as it recovers.
Amgen (AMGN) had a mixed quarterly earnings report as the company topped analysts' earnings expectations, but its full-year outlook missed the mark.
When it comes to dividend stocks, cash is king. These five stocks have huge cash balances and cash flows to keep the payouts coming.
Amgen stock is coiling like a spring. When the breakout comes, use AMGN call spreads to profit.
Wednesday’s Vital Data: Alibaba Group Holding Ltd (BABA), Amgen Inc. (AMGN) and Advanced Micro Devices, Inc. (AMD)
Alibaba (BABA) options jump on Baozun earnings, Amgen (AMGN) volume spikes ahead of FDA review and Advanced Micro (AMD) puts continue to pile up.
The Sell for Amgen (AMGN) this week is based on the most current relative pricing of its shares and stock market ratings.
Navellier RatingsPowered by Portfolio Grader